Pharmaceutical Executive-10-01-2013

Pharmaceutical Executive
Column

October 31, 2013

As the burden of promotional disclosure expands beyond US shores, understanding the rules and then controlling the cost of compliance is a strategic necessity.

Pharmaceutical Executive
Column

October 01, 2013

New drug delivery mechanisms and devices are an opportunity to build relationship with the ultimate customer: the patient.

Pharmaceutical Executive
Country Report

October 01, 2013

Rumor has it the BRIC palace is crumbling. Perhaps that's overdramatic, but at the very least the BRIC oven is cooling off. Where to now? The United States and Europe remain in a state of languid stagnation, while Asia and Africa are largely addressing basic healthcare needs with low-cost generic medicine.

Pharmaceutical Executive
Column

October 01, 2013

European efforts to crack down on safety and pricing issues in the marketing of medical devices may portend long-term problems for Big Pharma.

Pharmaceutical Executive
Column

October 01, 2013

Patient access is the new driver of change and progress in healthcare marketing, says a senior industry player in market development.

Pharmaceutical Executive
Column

October 01, 2013

Europe follows the United States with a harsh new spotlight on agreements that slow generic entry for medicines losing exclusivity.

Pharmaceutical Executive

Environmental changes on all sides of professional sale are forcing biopharmaceutical companies to select for new traits in the makeup of the field force function.

Pharmaceutical Executive
Column

October 01, 2013

Tension mounts over biosimilars, co-pay coupons, trade, and testing.

Pharmaceutical Executive

With revenues down and margins squeezed by a realigning payer pool, the power to price above the market is the ticket to the top-no discounts allowed.

Pharmaceutical Executive
Features

October 01, 2013

With key provisions of the Affordable Care Act set to launch this month, industry veteran Mason Tenaglia says the impact all depends on what you sell and where you sit.

Pharmaceutical Executive

Predictive analysis has been used to great effect in the finance, tech, retail, and telecoms industries. Can it also improve decision-making and health outcomes in life sciences?

Pharmaceutical Executive
From the Editor

October 01, 2013

Our October issue highlights a latent threat to Big Pharma: the behavioral mindset that may be best characterized as "ageing in place."